Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia
Pancreatology · 2024
DOI: 10.1016/j.pan.2024.10.008 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Pancreatology, 2024. Verfasst von Amanda Landers und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Otago, Christchurch, New Zealand. Electronic address: amanda.landers@otago.ac.nz. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Enzyme Replacement Therapy, Pancreatic Elastase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canterbury District Health Board, University of Auckland.
Abstract (Originalsprache)
OBJECTIVE: To investigate the practices of clinicians prescribing pancreatic enzyme replacement therapy (PERT) for unresectable pancreatic cancer in Aotearoa New Zealand and Australia. METHODS: A mixed media advertising campaign was used to recruit appropriate clinicians to complete a questionnaire that collected demographic data, information regarding prescribed medication, and awareness of PERT guidelines. RESULTS: The study recruited 161 clinicians, with 93 and 68 respondents from Aotearoa New Zealand and Australia respectively. Most respondents from both countries were experienced gastrointestinal surgeons and dietitians. Aotearoa New Zealand clinicians and dietitians used faecal elastase more frequently to diagnose PEI than other groups. Clinicians had a tendency to under-prescribe PERT, and to advise incorrectly on the timing of the medication. The majority of clinicians from Aotearoa New Zealand and Australia were not aware of any best practice clinical guidelines for PERT (70 % and 77 %, respectively). CONCLUSION: This study suggests clinicians are over-reliant on faecal elastase to diagnose PEI and are uncertain about the correct dose and timing of PERT for optimal patient benefit in those with unresectable pancreatic cancer. Most clinicians were not aware of best practice guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Otago, Christchurch, New Zealand. Electronic address: amanda.landers@otago.ac.nz.
- Nurse Maude Hospice Palliative Care Service, Nurse Maude Association, Christchurch, New Zealand.
- Nutrition and Dietetics, Te Whatu Ora, Te Toka Tumai, Auckland, New Zealand.
- Department of Medicine, University of Otago, Christchurch, New Zealand.
- University of Otago, Christchurch, New Zealand.
- Nurse Maude Hospice Palliative Care Service, Christchurch, New Zealand.
Förderung
- Canterbury District Health Board
- University of Auckland
Zitieren
APA
Landers, A., Brown, H., Russell, K., Fanning, N., Fu, F., McKenzie, C., Agar, M. R., Yenson, V. M., Clarke, K., & Windsor, J. (2024). Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia. Pancreatology. https://doi.org/10.1016/j.pan.2024.10.008
Vancouver
Landers A, Brown H, Russell K, Fanning N, Fu F, McKenzie C, et al. Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia. Pancreatology. 2024. doi:10.1016/j.pan.2024.10.008
BibTeX
@article{Landers2024,
author = {Landers, Amanda and Brown, Helen and Russell, Kylie and Fanning, Niamh and Fu, Fong and McKenzie, Clare and Agar, Meera R and Yenson, Vanessa M and Clarke, Kate and Windsor, John},
title = {Prescribing of pancreatic enzyme therapy for malabsorption in unresectable pancreatic cancer: Cross-sectional survey across New Zealand and Australia},
journal = {Pancreatology},
year = {2024},
doi = {10.1016/j.pan.2024.10.008}
}
EUVIMED